|
1）Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
2）Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91
|
|
|
|
|
|
3）Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92
|
|
|
|
|
|
4）Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-104
|
|
|
|
|
|
5）Komori M, Yasaka M, Kokuba K, et al. Intracranial hemorrhage during dabigatran treatment. Circ J. 2014; 78: 1335-41
|
|
|
|
|
6）Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369: 1206-14
|
|
|
|
|
|
7）Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation－the J-ROCKET AF study－. Circ J. 2012; 76: 2104-11
|
|
|
|
|
|
8）Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406-15
|
|
|
|
|
|
9）Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012; 87 Suppl 1: S141-5
|
|
|
|
|
|
10）Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013; 19: 446-51
|
|
|
|
|
|
11）Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371: 2141-2
|
|
|
|
|
|
12）Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015; Jun 22. [Epub ahead of print]
|
|
|
|
|
|
13）日本脳卒中学会 脳卒中ガイドライン委員会. 脳卒中治療ガイドライン2015
|
|
|
|
|
|
14）RE-SPECT ESUS. https://clinicaltrials.gov/ct2/show/nct02239120. Accessed February 1, 2015
|
|
|
|
|
|
15）NAVIGATE ESUS. https://clinicaltrials.gov/ct2/show/nct02313909. Accessed February 1, 2015
|
|
|
|
|